https://v3.pharmanews.devmesh.eu/story/729064/pharma-industry-asks-fda-for-more Rxwire en 2026-09-25T16:51:20Z Pharma industry asks FDA for more details on when one trial is enough https://v3.pharmanews.devmesh.eu/story/728884/syndax-pharmaceuticals-buy-the-pullback-ahead Rxwire en 2026-09-25T16:28:31Z Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts https://v3.pharmanews.devmesh.eu/story/728883/trump-seeks-to-produce-more-generic Rxwire en 2026-09-25T16:21:46Z Trump seeks to produce more generic drugs in the US https://v3.pharmanews.devmesh.eu/story/728642/to-get-drugmakers-into-ultra-rare Rxwire en 2026-09-25T15:41:48Z To get drugmakers into ultra-rare disease, the answer isn’t rare disease at all https://v3.pharmanews.devmesh.eu/story/728629/2026-ims-iaso-bio-presents-first Rxwire en 2026-09-25T15:32:00Z 2026 IMS | IASO Bio Presents First-in-Human Phase 1 Data of RD140, a Fully Human BCMA/GPRC5D Dual-Targeted FasT CAR-T https://v3.pharmanews.devmesh.eu/story/721909/lilly-wins-fda-nod-for-once Rxwire en 2026-09-24T11:07:58Z Lilly wins FDA nod for once-weekly insulin product, Onswik https://v3.pharmanews.devmesh.eu/story/728407/2026-ims-updated-fumanba-1-analysis Rxwire en 2026-09-25T14:54:00Z 2026 IMS | Updated FUMANBA-1 Analysis of IASO Bio's FUCASO Reveals That In Vivo Durable Persistence of CAR-T cells Is Associated with Sustained MRD Negativity and Delayed Disease Progression https://v3.pharmanews.devmesh.eu/story/728180/opinion-fda-commissioner-nominee-heidi-overton Rxwire en 2026-09-25T14:39:38Z Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug https://v3.pharmanews.devmesh.eu/story/727902/nektar-prevails-in-legal-battle-with Rxwire en 2026-09-25T14:04:34Z Nektar prevails in legal battle with Lilly over broken rezpeg partnership https://v3.pharmanews.devmesh.eu/story/727901/kali-therapeutics-named-to-the-2026 Rxwire en 2026-09-25T14:01:00Z Kali Therapeutics Named to the 2026 Endpoints 11, Recognizing Biotech's Most Promising Startups https://v3.pharmanews.devmesh.eu/story/727900/endpoints-11-2026-winner-kali-looked Rxwire en 2026-09-25T14:00:59Z Endpoints 11 2026 winner Kali looked at China for pipeline drugs, then turned in-house https://v3.pharmanews.devmesh.eu/story/727899/endpoints-11-2026-winner-azalea-melds Rxwire en 2026-09-25T14:00:58Z Endpoints 11 2026 winner Azalea melds gene editing and CAR-T https://v3.pharmanews.devmesh.eu/story/727898/endpoints-11-2026-winner-newlimit-searches Rxwire en 2026-09-25T14:00:55Z Endpoints 11 2026 winner NewLimit searches for a new class of anti-aging drugs https://v3.pharmanews.devmesh.eu/story/727894/endpoints-11-2026-winner-sonothera-has Rxwire en 2026-09-25T14:00:42Z Endpoints 11 2026 winner SonoThera has a new approach to non-viral gene therapy https://v3.pharmanews.devmesh.eu/story/727893/endpoints-11-2026-winner-medici-believes Rxwire en 2026-09-25T14:00:38Z Endpoints 11 2026 winner Medici believes the future of cancer therapy is personalized https://v3.pharmanews.devmesh.eu/story/727891/biotech-s-best-startups-of-2026 Rxwire en 2026-09-25T14:00:30Z Biotech's best startups of 2026: Meet this year's Endpoints 11 https://v3.pharmanews.devmesh.eu/story/727890/endpoints-11-2026-winner-k2-therapeutics Rxwire en 2026-09-25T14:00:22Z Endpoints 11 2026 winner K2 Therapeutics looks to marry China’s speed with global expertise https://v3.pharmanews.devmesh.eu/story/727889/endpoints-11-2026-winner-vivodyne-s Rxwire en 2026-09-25T14:00:06Z Endpoints 11 2026 winner Vivodyne’s human tissue factory could change drug testing https://v3.pharmanews.devmesh.eu/story/728347/doctor-killed-in-double-stabbing-thyroid Rxwire en 2026-09-25T13:36:13Z Doctor Killed in Double Stabbing; Thyroid Pill Recall Upgraded; HHS Nominee Advances https://v3.pharmanews.devmesh.eu/story/727656/adarx-raises-446m-in-biotech-s Rxwire en 2026-09-25T13:34:11Z ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public https://v3.pharmanews.devmesh.eu/story/727655/stat-pharmalittle-we-re-reading-about Rxwire en 2026-09-25T13:32:10Z STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and more https://v3.pharmanews.devmesh.eu/story/727812/is-the-next-generation-of-chinese Rxwire en 2026-09-25T13:30:00Z Is the next generation of Chinese biotech ready to go global alone? https://v3.pharmanews.devmesh.eu/story/727654/j-j-legend-tout-long-term Rxwire en 2026-09-25T13:25:46Z J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma https://v3.pharmanews.devmesh.eu/story/727478/novo-pursues-long-acting-obesity-drugs Rxwire en 2026-09-25T13:21:00Z Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data https://v3.pharmanews.devmesh.eu/story/727977/why-astrazeneca-still-looks-underrated-despite Rxwire en 2026-09-25T13:15:45Z Why AstraZeneca Still Looks Underrated Despite Strong EPS Momentum https://v3.pharmanews.devmesh.eu/story/727277/zifo-s-ai-powered-clinical-reporting Rxwire en 2026-09-25T13:00:00Z Zifo's AI-Powered Clinical Reporting Solution Named Runner-Up in the 2026 CDISC AI Innovation Challenge https://v3.pharmanews.devmesh.eu/story/728397/bristol-myers-squibb-patents-new-nik Rxwire en 2026-09-25T13:00:00Z Bristol Myers Squibb patents new NIK inhibitors https://v3.pharmanews.devmesh.eu/story/728398/syndax-pharmaceuticals-synthesizes-new-menin-mll Rxwire en 2026-09-25T13:00:00Z Syndax Pharmaceuticals synthesizes new menin/MLL interaction inhibitors https://v3.pharmanews.devmesh.eu/story/728400/sotio-s-sot-106-designated-orphan Rxwire en 2026-09-25T13:00:00Z Sotio’s SOT-106 designated orphan drug for soft tissue sarcoma https://v3.pharmanews.devmesh.eu/story/728404/prime-medicine-s-pm-647-gains Rxwire en 2026-09-25T13:00:00Z Prime Medicine’s PM-647 gains IND approval for AATD https://v3.pharmanews.devmesh.eu/story/722777/xtalpi-submits-u-s-fda-ind Rxwire en 2026-09-25T00:30:00Z XtalPi Submits U.S. FDA IND Application for KQTD-126, a Potential First-in-Class, Gut-Restricted Pan-TRK Inhibitor for Chronic Intestinal Pain https://v3.pharmanews.devmesh.eu/story/727598/nimbus-used-ai-to-help-develop Rxwire en 2026-09-25T12:57:37Z Nimbus used AI to help develop Takeda’s $4B psoriasis bet. Here’s where it’s taking the tech next https://v3.pharmanews.devmesh.eu/story/727597/basecamp-raises-140m-before-the-clinic Rxwire en 2026-09-25T12:57:20Z Basecamp raises $140M before the clinic; J&J and Compass’ potential rivalry https://v3.pharmanews.devmesh.eu/story/727100/merck-expands-welireg-s-use-to Rxwire en 2026-09-25T12:37:47Z Merck expands Welireg's use to broader set of kidney cancer patients https://v3.pharmanews.devmesh.eu/story/722008/earendil-s-ai-platform-lands-1 Rxwire en 2026-09-24T16:00:00Z Earendil’s AI platform lands $1.5B Genentech collaboration https://v3.pharmanews.devmesh.eu/story/727201/eu-clears-first-drug-therapy-for Rxwire en 2026-09-25T12:25:27Z EU clears first drug therapy for rare disease cALD https://v3.pharmanews.devmesh.eu/story/726366/nih-funding-cuts-delayed-a-promising Rxwire en 2026-09-25T11:00:01Z NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn't have. https://v3.pharmanews.devmesh.eu/story/726750/second-nrf2-degrader-enters-clinical-development Rxwire en 2026-09-25T12:00:00Z Second NRF2 Degrader Enters Clinical Development: Nutshell Therapeutics' NTS231 Received FDA IND Clearance https://v3.pharmanews.devmesh.eu/story/726668/before-ayushman-bharat-families-sold-their Rxwire en 2026-09-25T11:48:35Z Before Ayushman Bharat, families sold their homes to afford treatment: J P Nadda https://v3.pharmanews.devmesh.eu/story/726566/johnson-johnson-announces-tremfya-guselkumab-is Rxwire en 2026-09-25T11:30:00Z Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study https://v3.pharmanews.devmesh.eu/story/726882/nektar-gains-5-as-jury-awards Rxwire en 2026-09-25T11:26:18Z Nektar gains 5% as jury awards $90M plus interest in Lilly trial https://v3.pharmanews.devmesh.eu/story/726667/fda-starts-speedy-review-of-imfinzi Rxwire en 2026-09-25T11:21:48Z FDA starts speedy review of Imfinzi in bladder cancer https://v3.pharmanews.devmesh.eu/story/721960/roche-atavistik-bio-partner-on-allosteric Rxwire en 2026-09-24T13:28:56Z Roche, Atavistik Bio partner on allosteric drug discovery https://v3.pharmanews.devmesh.eu/story/722068/merck-welireg-eisai-lenvima-combo-approved Rxwire en 2026-09-24T20:32:12Z Merck Welireg, Eisai Lenvima combo approved for kidney cancer https://v3.pharmanews.devmesh.eu/story/726337/alnylam-alumni-led-rnai-biotech-city Rxwire en 2026-09-25T11:04:51Z Alnylam alumni-led RNAi biotech City Therapeutics files for IPO https://v3.pharmanews.devmesh.eu/story/727296/alnylam-alumni-lead-rnai-biotech-city Rxwire en 2026-09-25T11:04:51Z Alnylam alumni lead RNAi biotech City Therapeutics to IPO filing https://v3.pharmanews.devmesh.eu/story/726336/travere-ceo-eric-dube-on-deciding Rxwire en 2026-09-25T11:00:47Z Travere CEO Eric Dube on deciding to leave; Roche tees up a board seat for ex-Takeda chief https://v3.pharmanews.devmesh.eu/story/726666/lord-s-mark-advances-ai-breast Rxwire en 2026-09-25T11:00:37Z Lord’s Mark advances AI breast cancer screening towards clinical trials https://v3.pharmanews.devmesh.eu/story/726365/novo-is-betting-on-its-next Rxwire en 2026-09-25T11:00:01Z Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s https://v3.pharmanews.devmesh.eu/story/726327/single-infusion-of-carvykti-ciltacabtagene-autoleucel Rxwire en 2026-09-25T11:00:00Z Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma https://v3.pharmanews.devmesh.eu/story/722057/fda-commissioner-nominee-overton-rebuffs-questions Rxwire en 2026-09-24T19:36:11Z FDA commissioner nominee Overton rebuffs questions about Trump medical claims https://v3.pharmanews.devmesh.eu/story/726881/solid-biosciences-a-funded-challenge-to Rxwire en 2026-09-25T10:49:40Z Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy's Limitations https://v3.pharmanews.devmesh.eu/story/726326/ec-approves-first-treatment-for-rare Rxwire en 2026-09-25T10:47:35Z EC approves first treatment for rare neurodegenerative disease https://v3.pharmanews.devmesh.eu/story/725170/novo-signs-up-to-1-3b Rxwire en 2026-09-25T07:11:15Z Novo signs up to $1.3B deal for Nanexa drug-delivery technology https://v3.pharmanews.devmesh.eu/story/727596/roche-and-earendil-forge-1-5bn Rxwire en 2026-09-25T10:27:57Z Roche and Earendil forge $1.5bn bispecific discovery deal https://v3.pharmanews.devmesh.eu/story/728041/fierce-pharma-week-a-look-at Rxwire en 2026-09-25T10:10:00Z Fierce Pharma Week: A look at the biggest trends, campaigns and conversations https://v3.pharmanews.devmesh.eu/story/726264/supreme-court-backs-delhi-hc-orders Rxwire en 2026-09-25T10:09:13Z Supreme Court backs Delhi HC orders in Daiichi-Fortis dispute, clears way for forensic audit https://v3.pharmanews.devmesh.eu/story/721917/kyverna-builds-case-for-car-t Rxwire en 2026-09-24T11:58:00Z Kyverna builds case for CAR-T in stiff person syndrome https://v3.pharmanews.devmesh.eu/story/725884/the-independent-pharmacy-opportunity-pharma-marketers Rxwire en 2026-09-25T10:00:00Z The independent pharmacy opportunity pharma marketers are overlooking https://v3.pharmanews.devmesh.eu/story/727130/milestone-begins-canadian-enrolment-in-phase Rxwire en 2026-09-25T09:41:55Z Milestone begins Canadian enrolment in Phase III AFib-RVR trial https://v3.pharmanews.devmesh.eu/story/725880/mhra-approves-pharma-mar-s-lurbinectedin Rxwire en 2026-09-25T09:40:00Z MHRA approves Pharma Mar’s lurbinectedin for extensive-stage small cell lung cancer https://v3.pharmanews.devmesh.eu/story/725878/heard-on-the-street-there-is Rxwire en 2026-09-25T09:30:00Z Heard on the Street: There is areal opportunity for pill-form peptides to hit big pharma’s most profitable franchises https://v3.pharmanews.devmesh.eu/story/721906/u-s-food-and-drug-administration Rxwire en 2026-09-24T10:45:00Z U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes https://v3.pharmanews.devmesh.eu/story/725941/ona-therapeutics-moves-to-phase-i Rxwire en 2026-09-25T09:09:57Z Ona Therapeutics moves to Phase I with ADC for advanced cancers https://v3.pharmanews.devmesh.eu/story/727745/fierce-pharma-asia-lilly-s-3 Rxwire en 2026-09-25T09:04:00Z Fierce Pharma Asia—Lilly’s $3.35B InnoCare deal; Korea’s breakthrough; China’s 5-year biotech plan https://v3.pharmanews.devmesh.eu/story/726880/prime-medicine-stock-jumps-8-after Rxwire en 2026-09-25T09:03:39Z Prime Medicine stock jumps 8% after FDA clears PM647 trial https://v3.pharmanews.devmesh.eu/story/727367/eli-lilly-blasted-for-promotional-and Rxwire en 2026-09-25T09:02:00Z Eli Lilly blasted for ‘promotional and emotive’ language in GLP-1 press release https://v3.pharmanews.devmesh.eu/story/725747/new-crispr-based-tool-enables-genome Rxwire en 2026-09-25T09:00:58Z New CRISPR-Based Tool Enables Genome-Wide Mutagenesis of Bacteriophages https://v3.pharmanews.devmesh.eu/story/725877/vilnius-university-develops-photoredox-method-to Rxwire en 2026-09-25T08:58:00Z Vilnius University develops photoredox method to accelerate drug discovery https://v3.pharmanews.devmesh.eu/story/725560/wnt-drug-gives-msd-first-eye Rxwire en 2026-09-25T08:40:34Z Wnt drug gives MSD first eye disease win after EyeBio deal https://v3.pharmanews.devmesh.eu/story/725508/how-big-tobacco-flooded-the-fda Rxwire en 2026-09-25T08:30:00Z How Big Tobacco flooded the FDA with public comments to kill a menthol cigarette ban https://v3.pharmanews.devmesh.eu/story/725559/ai-agents-target-drug-safety-protein Rxwire en 2026-09-25T08:25:00Z AI agents target drug safety, protein discovery and secure health data analysis https://v3.pharmanews.devmesh.eu/story/727129/clywedog-reports-final-phase-ib-trial Rxwire en 2026-09-25T08:22:04Z Clywedog reports final Phase Ib trial results for balomenib https://v3.pharmanews.devmesh.eu/story/725369/theialife-s-race-to-bring-a Rxwire en 2026-09-25T08:00:00Z Theialife’s race to bring a childhood myopia treatment to market https://v3.pharmanews.devmesh.eu/story/725388/cryoport-strong-pipeline-of-cell-and Rxwire en 2026-09-25T07:26:56Z Cryoport: Strong Pipeline Of Cell And Gene Therapy Approvals https://v3.pharmanews.devmesh.eu/story/725115/which-control-system-is-best-for Rxwire en 2026-09-25T07:00:00Z Which control system is best for personalised medicine? https://v3.pharmanews.devmesh.eu/story/725828/indivior-ends-pam-drug-collab-with Rxwire en 2026-09-25T05:24:00Z Indivior ends PAM drug collab with Addex ahead of Supernus merger https://v3.pharmanews.devmesh.eu/story/725169/roche-s-genentech-inks-1-5b Rxwire en 2026-09-25T02:52:00Z Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendil https://v3.pharmanews.devmesh.eu/story/725168/adarx-scores-upsized-446m-ipo-while Rxwire en 2026-09-25T02:47:00Z ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans https://v3.pharmanews.devmesh.eu/story/723331/uchicago-medicine-finaliza-la-fase-de Rxwire en 2026-09-25T02:12:00Z UChicago Medicine finaliza la fase de construcción del Pabellón Oncológico de la Fundación AbbVie, acercando a la realidad una nueva era en la atención del cáncer https://v3.pharmanews.devmesh.eu/story/723163/rnai-drug-specialist-adarx-raises-446m Rxwire en 2026-09-25T00:36:00Z RNAi drug specialist ADARx raises $446M IPO https://v3.pharmanews.devmesh.eu/story/722080/alphabet-and-meta-now-spend-nearly Rxwire en 2026-09-24T22:31:12Z Alphabet and Meta now spend nearly as much on R&D as pharma’s 10 largest drugmakers https://v3.pharmanews.devmesh.eu/story/722079/global-autoimmune-treatment-market-to-reach Rxwire en 2026-09-24T22:15:00Z Global Autoimmune Treatment Market to Reach USD 321.95 Billion by 2034, Driven by Rising Prevalence of Autoimmune Diseases, Growing Adoption of Biologics, and Advances in Precision Medicine Says Maximize Market Research https://v3.pharmanews.devmesh.eu/story/722476/fda-nominee-voices-support-for-vaccines Rxwire en 2026-09-24T21:42:11Z FDA Nominee Voices Support for Vaccines at Senate Hearing Scrutinizing Trump's Moves https://v3.pharmanews.devmesh.eu/story/722075/grail-multicancer-detection-test-wins-fda Rxwire en 2026-09-24T21:08:00Z Grail multicancer detection test wins FDA advisers’ backing https://v3.pharmanews.devmesh.eu/story/722074/muscle-cell-calcium-channel-structure-synchronicity Rxwire en 2026-09-24T21:05:43Z Muscle Cell Calcium Channel Structure, Synchronicity Could Advance Muscle Disease Therapeutics https://v3.pharmanews.devmesh.eu/story/722072/fda-approves-new-option-for-previously Rxwire en 2026-09-24T20:56:41Z FDA Approves New Option for Previously Treated Bile Duct Cancer https://v3.pharmanews.devmesh.eu/story/721878/stat-heidi-overton-trump-s-pick Rxwire en 2026-09-24T08:30:00Z STAT+: Heidi Overton, Trump’s pick for FDA head, to face questions at Senate hearing https://v3.pharmanews.devmesh.eu/story/722071/where-does-fda-nominee-overton-stand Rxwire en 2026-09-24T20:46:00Z Where does FDA nominee Overton stand on vaccines and other key pharma issues? https://v3.pharmanews.devmesh.eu/story/722066/new-study-highlights-clinical-need-for Rxwire en 2026-09-24T20:30:00Z New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™ https://v3.pharmanews.devmesh.eu/story/722064/stat-fda-commissioner-nominee-heidi-overton Rxwire en 2026-09-24T20:21:32Z STAT+: FDA commissioner nominee Heidi Overton keeps opinions to herself in Senate hearing https://v3.pharmanews.devmesh.eu/story/722063/renibus-therapeutics-announces-participation-at-the Rxwire en 2026-09-24T20:05:00Z Renibus Therapeutics Announces Participation at the Oppenheimer Private Life Sciences Company Showcase https://v3.pharmanews.devmesh.eu/story/722060/jnc-targets-bigger-molecules-with-cellufine Rxwire en 2026-09-24T19:48:59Z JNC Targets Bigger Molecules with Cellufine https://v3.pharmanews.devmesh.eu/story/722059/pfizer-poised-for-gains-with-a Rxwire en 2026-09-24T19:48:10Z Pfizer: Poised For Gains With A New Drug Pipeline And Cost-Cutting Plans https://v3.pharmanews.devmesh.eu/story/722056/the-fda-s-overton-era-and Rxwire en 2026-09-24T19:30:38Z The FDA’s Overton era, and dispatches from Shanghai https://v3.pharmanews.devmesh.eu/story/722055/ac-immune-buy-continued-aci-7104 Rxwire en 2026-09-24T19:21:38Z AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions https://v3.pharmanews.devmesh.eu/story/722054/nsf-funds-iss-national-lab-sponsored Rxwire en 2026-09-24T19:21:00Z NSF Funds ISS National Lab-Sponsored Projects to Advance Applications in Electronics Cooling and Drug Delivery https://v3.pharmanews.devmesh.eu/story/722053/uchicago-medicine-completes-construction-phase-of Rxwire en 2026-09-24T19:07:00Z UChicago Medicine completes construction phase of AbbVie Foundation Cancer Pavilion, bringing new era of cancer care closer to reality https://v3.pharmanews.devmesh.eu/story/724551/why-we-like-starbucks-latest-turnaround Rxwire en 2026-09-24T19:06:08Z Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly https://v3.pharmanews.devmesh.eu/story/721820/fda-adcomm-votes-in-favor-of Rxwire en 2026-09-23T18:23:52Z FDA adcomm votes in favor of benefit-risk of Grail’s cancer test https://v3.pharmanews.devmesh.eu/story/722051/crispr-therapeutics-why-ai-giant-anthropic Rxwire en 2026-09-24T18:59:20Z Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing https://v3.pharmanews.devmesh.eu/story/722050/possible-drug-drug-interactions-flagged-for Rxwire en 2026-09-24T18:59:17Z Possible Drug-Drug Interactions Flagged for Older Americans https://v3.pharmanews.devmesh.eu/story/722049/fda-slams-glp-1-compounder-over Rxwire en 2026-09-24T18:53:03Z FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’ https://v3.pharmanews.devmesh.eu/story/721863/altruist-biologics-preps-for-production-following Rxwire en 2026-09-24T04:29:23Z Altruist Biologics preps for production following EMA GMP certification https://v3.pharmanews.devmesh.eu/story/722046/lilly-again-looks-to-china-for Rxwire en 2026-09-24T18:31:17Z Lilly Again Looks to China for New Drugs, Paying InnoCare $100M to Start R&D Pact https://v3.pharmanews.devmesh.eu/story/722044/nurse-spreads-vaccine-misinfo-md-vs Rxwire en 2026-09-24T18:30:07Z Nurse Spreads Vaccine Misinfo; MD vs PBM; Growing Pains or Red Flags? https://v3.pharmanews.devmesh.eu/story/722042/riaan-s-therapeutic-odyssey-chapter-4 Rxwire en 2026-09-24T18:20:55Z Riaan’s Therapeutic Odyssey – Chapter 4: The Drug Developers https://v3.pharmanews.devmesh.eu/story/721980/senators-grill-fda-nominee-heidi-overton Rxwire en 2026-09-24T14:32:38Z Senators grill FDA nominee Heidi Overton https://v3.pharmanews.devmesh.eu/story/722034/ligand-avencell-ink-financing-deal-worth Rxwire en 2026-09-24T17:17:57Z Ligand, AvenCell ink financing deal worth up to $47M for CAR-T therapies https://v3.pharmanews.devmesh.eu/story/722033/experimental-drug-could-reverse-multiple-sclerosis Rxwire en 2026-09-24T17:16:54Z Experimental Drug Could Reverse Multiple Sclerosis Damage https://v3.pharmanews.devmesh.eu/story/722013/fgfr2-inhibitor-lyrfigtu-wins-fda-approval Rxwire en 2026-09-24T16:00:00Z FGFR2 inhibitor Lyrfigtu wins FDA approval for bile duct cancer https://v3.pharmanews.devmesh.eu/story/722022/cullinan-drops-after-delaying-early-stage Rxwire en 2026-09-24T16:37:46Z Cullinan drops after delaying early-stage trial data for arthritis therapy https://v3.pharmanews.devmesh.eu/story/721956/eli-lilly-s-weekly-insulin-shot Rxwire en 2026-09-24T13:20:58Z Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry https://v3.pharmanews.devmesh.eu/story/722019/sanofi-healthcare-buys-15-2-stake Rxwire en 2026-09-24T16:14:14Z Sanofi Healthcare buys 15.2% stake in Sanofi India for Rs 1,068 crore https://v3.pharmanews.devmesh.eu/story/722018/the-30-minute-medicine-problem Rxwire en 2026-09-24T16:07:19Z The 30-Minute Medicine Problem https://v3.pharmanews.devmesh.eu/story/721858/grail-s-galleri-test-wins-endorsement Rxwire en 2026-09-24T00:57:24Z GRAIL's Galleri test wins endorsement from FDA panel https://v3.pharmanews.devmesh.eu/story/722003/lilly-extends-china-innovation-push-in Rxwire en 2026-09-24T16:00:00Z Lilly extends China innovation push in $3.35B Innocare deal https://v3.pharmanews.devmesh.eu/story/722004/n-of-1-therapies-to-address Rxwire en 2026-09-24T16:00:00Z N-of-1 therapies to address rare diseases with no commercial interest https://v3.pharmanews.devmesh.eu/story/722006/regulatory-fda-nods-for-intrabio-nuvation Rxwire en 2026-09-24T16:00:00Z Regulatory: FDA nods for Intrabio, Nuvation, Fempulse, Xenix and more https://v3.pharmanews.devmesh.eu/story/722009/an-instinct-about-atavistik-roche-signs Rxwire en 2026-09-24T16:00:00Z An instinct about Atavistik? Roche signs $1.9B-plus deal https://v3.pharmanews.devmesh.eu/story/722010/awiqli-insulin-this-time-for-lilly Rxwire en 2026-09-24T16:00:00Z Awiqli insulin, this time for Lilly, with FDA-cleared Onswik https://v3.pharmanews.devmesh.eu/story/722012/enveda-raises-a-311m-series-e Rxwire en 2026-09-24T16:00:00Z Enveda raises a $311M series E for pipeline of plant-discovered molecules https://v3.pharmanews.devmesh.eu/story/722014/dme-red-flag-in-merck-brunello Rxwire en 2026-09-24T16:00:00Z DME red flag in Merck Brunello phase III? Surrozen finishes rich https://v3.pharmanews.devmesh.eu/story/722002/grail-sets-new-52-week-high Rxwire en 2026-09-24T15:56:29Z GRAIL sets new 52-week high as FDA panel backs cancer test https://v3.pharmanews.devmesh.eu/story/722001/acrobiosystems-introduces-cho-direct-and-acro Rxwire en 2026-09-24T15:55:00Z ACROBiosystems Introduces CHO-Direct and ACRO AIx to Accelerate AI-driven Drug Discovery https://v3.pharmanews.devmesh.eu/story/721998/marani-health-receives-fda-clearance-for Rxwire en 2026-09-24T15:45:00Z Marani Health Receives FDA Clearance for M•care System, Clearing the Path Toward Commercial Launch https://v3.pharmanews.devmesh.eu/story/721997/acadia-pharmaceuticals-remlifanserin-is-in-trouble Rxwire en 2026-09-24T15:43:46Z Acadia Pharmaceuticals: Remlifanserin Is In Trouble https://v3.pharmanews.devmesh.eu/story/721996/video-on-function-focused-antibody-discovery Rxwire en 2026-09-24T15:37:10Z Video on function-focused antibody discovery workflows with Envisia https://v3.pharmanews.devmesh.eu/story/721994/merck-reveals-study-success-and-possible Rxwire en 2026-09-24T15:34:00Z Merck reveals study success, and possible safety worries, for eye drug hopeful https://v3.pharmanews.devmesh.eu/story/721993/msd-s-dme-drug-could-challenge Rxwire en 2026-09-24T15:32:56Z MSD’s DME drug could challenge anti-VEGF reign, late-stage study suggests https://v3.pharmanews.devmesh.eu/story/721992/fda-panel-narrowly-backs-multi-cancer Rxwire en 2026-09-24T15:32:21Z FDA Panel Narrowly Backs Multi-Cancer Blood Test Despite Doubts It Works https://v3.pharmanews.devmesh.eu/story/721991/roche-secures-separate-discovery-deals-with Rxwire en 2026-09-24T15:30:48Z Roche secures separate discovery deals with Atavistik, Earendil https://v3.pharmanews.devmesh.eu/story/721990/10-year-data-back-early-start Rxwire en 2026-09-24T15:30:23Z 10-Year Data Back Early Start to Biologics in Arthritic Diseases https://v3.pharmanews.devmesh.eu/story/721989/sarepta-to-pay-regenxbio-39m-to Rxwire en 2026-09-24T15:05:48Z Sarepta to pay Regenxbio $39M to settle gene therapy claims; Vida eyes fourth fund https://v3.pharmanews.devmesh.eu/story/721926/acadia-falls-after-mid-stage-trial Rxwire en 2026-09-24T12:03:08Z Acadia falls after mid-stage trial setback for Alzheimer’s psychosis therapy https://v3.pharmanews.devmesh.eu/story/721982/johnson-county-clintrials-jcct-rebrands-as Rxwire en 2026-09-24T14:45:00Z Johnson County ClinTrials (JCCT) Rebrands as Sequoia Clinical Research https://v3.pharmanews.devmesh.eu/story/721806/astrazeneca-granted-eu-label-expansion-for Rxwire en 2026-09-23T17:50:07Z AstraZeneca granted EU label expansion for COPD therapy, Trixeo in asthma https://v3.pharmanews.devmesh.eu/story/721981/six-reasons-to-register-for-drug Rxwire en 2026-09-24T14:38:28Z Six reasons to register for Drug Discovery Innovators & Investors UK Conference https://v3.pharmanews.devmesh.eu/story/721979/chronic-kidney-disease-market-5-emerging Rxwire en 2026-09-24T14:31:00Z Chronic Kidney Disease Market: 5 Emerging Therapies to Watch as the Treatment Landscape Expected to Evolve by 2036 | DelveInsight https://v3.pharmanews.devmesh.eu/story/721977/arcturus-raised-to-buy-at-citi Rxwire en 2026-09-24T14:26:38Z Arcturus raised to Buy at Citi after mid-stage trial data for liver disease drug https://v3.pharmanews.devmesh.eu/story/721974/acadia-slides-on-phase-2-miss Rxwire en 2026-09-24T14:25:32Z Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward https://v3.pharmanews.devmesh.eu/story/721973/daiichi-sankyo-expands-turbine-collaboration-to Rxwire en 2026-09-24T14:17:00Z Daiichi Sankyo expands Turbine collaboration to accelerate ADC discovery https://v3.pharmanews.devmesh.eu/story/721972/lilly-s-latest-china-drug-deal Rxwire en 2026-09-24T14:14:00Z Lilly’s latest China drug deal; Immunovant’s setback in lupus https://v3.pharmanews.devmesh.eu/story/724549/trump-s-fda-pick-heidi-overton Rxwire en 2026-09-24T14:10:00Z Trump's FDA pick Heidi Overton calls vaccines, mifepristone safe and effective in confirmation hearing https://v3.pharmanews.devmesh.eu/story/721971/elephas-biosciences-and-tes-pharma-collaborate Rxwire en 2026-09-24T14:00:00Z ELEPHAS BIOSCIENCES AND TES PHARMA COLLABORATE TO ADVANCE TRANSLATIONAL RESEARCH FOR LUNG CANCER THERAPY https://v3.pharmanews.devmesh.eu/story/721968/eli-lilly-outlays-3-35bn-for Rxwire en 2026-09-24T13:57:40Z Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare https://v3.pharmanews.devmesh.eu/story/721967/merck-s-experimental-eye-drug-matches Rxwire en 2026-09-24T13:51:12Z Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge https://v3.pharmanews.devmesh.eu/story/721964/novo-nordisk-capital-markets-day-reveals Rxwire en 2026-09-24T13:39:59Z Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine https://v3.pharmanews.devmesh.eu/story/721963/united-therapeutics-sagimet-drop-after-goldman Rxwire en 2026-09-24T13:37:43Z United Therapeutics, Sagimet drop after Goldman Sachs Sell ratings https://v3.pharmanews.devmesh.eu/story/721959/kyverna-steps-closer-to-fda-first Rxwire en 2026-09-24T13:27:54Z Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data https://v3.pharmanews.devmesh.eu/story/721958/stat-pharmalittle-we-re-reading-about Rxwire en 2026-09-24T13:21:50Z STAT+: Pharmalittle: We’re reading about the FDA commissioner nominee, a Lilly partnership in China, and more